deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02485301

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa

Sponsor: GlaxoSmithKline

Conditions Virus Diseases
Interventions GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A) Placebo
Updated 9 times since 2017 Last updated: Dec 4, 2017 Started: Jul 15, 2015 Primary completion: Dec 23, 2016 Completion: Dec 23, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02485301, this PHASE2 trial focuses on Virus Diseases and remains completed. Sponsored by GlaxoSmithKline, it has been updated 9 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshotActive Not Recruiting~Mar 2017 – ~Jan 2018 · 10 months · monthly snapshotCompleted~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 11 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jan 2018 — Jun 2018 [monthly]

    Completed PHASE2

  2. Mar 2017 — Jan 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations